Carmela Caballero

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

Dorothea Wagner, Heike I. Grabsch, Murielle Mauer et al. · BMC Cancer · 2019 · 117 citations · Full text

Medicine, Oncology, Perioperative Medicine +17

Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas

Isabel Zudaire, María D. Odero, Carmela Caballero et al. · Histopathology · 2002 · 47 citations · Full text

Life Sciences, Genetics, Oncology +14

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

Sibylle Loibl, Jacek Jassem, Amir Sonnenblick et al. · Journal of Clinical Oncology · 2024 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

From a Comic Opera to Surcare an Open Letter to Whom Clinical Research in Surgery Is a Concern

Serge Évrard, Graeme J. Poston, Carmela Caballero et al. · Annals of Surgery · 2016 · 21 citations

Medicine, Oncology, Surgery +7

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

Evandro de Azambuja, Elisa Agostinetto, Marion Procter et al. · ESMO Open · 2023 · 21 citations · Full text

Medicine, Oncology, Pharmacology +16